Clinical Scorecard: Comparison of Bendamustine and Fludarabine/Cyclophosphamide Lymphodepletion Before BCMA CAR-T Cell Therapy in Patients with Multiple Myeloma
At a Glance
Category
Detail
Condition
Relapsed multiple myeloma
Key Mechanisms
Lymphodepletion prior to BCMA CAR-T therapy enhances immune and cytokine environment for CAR-T expansion and has direct cytotoxic effects
Target Population
Patients with relapsed multiple myeloma receiving standard of care BCMA CAR-T therapy (ide-cel or cilta-cel)
Bendamustine lymphodepletion is effective and safe as an alternative to fludarabine/cyclophosphamide (Flu/Cy) during fludarabine shortage.
No significant difference in CAR-T cell expansion or hematologic recovery trajectories between bendamustine and Flu/Cy lymphodepletion.
Similar baseline patient characteristics and response rates observed between bendamustine and Flu/Cy cohorts.
Guideline-Based Recommendations
Diagnosis
Use International Myeloma Working Group (IMWG) Criteria for response assessment in multiple myeloma.
Management
Administer lymphodepletion prior to BCMA CAR-T therapy to optimize CAR-T expansion and efficacy.
Standard lymphodepletion regimen includes fludarabine and cyclophosphamide; bendamustine can be used as an alternative during fludarabine shortage.
Bendamustine dosing: 90 mg/m2 on days -4 and -3 prior to CAR-T infusion.
Flu/Cy dosing: cyclophosphamide 300 mg/m2 and fludarabine up to 30 mg/m2 on days -5, -4, and -3 prior to CAR-T infusion.
Monitoring & Follow-up
Assess cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) using ASTCT criteria.
Monitor hematologic toxicity using CTCAE version 5.0.
Track absolute lymphocyte count (ALC), absolute neutrophil count (ANC), platelet count, and hemoglobin pre- and post-lymphodepletion and CAR-T infusion.
Risks
Potential hematologic toxicities including neutropenia and thrombocytopenia; no significant difference in toxicity profiles between bendamustine and Flu/Cy observed.
CRS and ICANS remain risks post-CAR-T therapy and require close monitoring.
Patient & Prescribing Data
56 patients with relapsed multiple myeloma receiving BCMA CAR-T therapy; 14 received bendamustine and 42 received Flu/Cy lymphodepletion.
Bendamustine lymphodepletion achieved effective lymphodepletion with comparable CAR-T expansion and hematologic recovery to Flu/Cy, supporting its use as an alternative during fludarabine shortages.
Clinical Best Practices
Use propensity score weighting to balance patient characteristics when comparing lymphodepletion regimens in clinical studies.
Adjust fludarabine dosing based on creatinine clearance per institutional protocols.
Consider timing of lymphodepletion dosing relative to CAR-T infusion day (day 0) for optimal outcomes.
Monitor lymphocyte recovery trajectory up to at least 90 days post-CAR-T infusion.
Evaluate CAR-T expansion by flow cytometry to assess treatment efficacy.
by Surbhi Sidana, Hitomi Hosoya, Alexandria Jensen, Lawrence Liu, Anmol Goyal, Vanna Hovanky, Bita Sahaf, Sushma Bharadwaj, Theresa Latchford, Sally Arai, Sheryl Leahy, Matthew Mei, Lihua E. Budde, Lori S. Muffly, Matthew J. Frank, Saurabh Dahiya, Myo Htut, David Miklos, Murali Janakiram
